{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:08:35Z","timestamp":1785409715742,"version":"3.56.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004781","name":"Institut Pengurusan dan Pemantauan Penyelidikan, Universiti Malaya","doi-asserted-by":"publisher","award":["UMREG060-2024"],"award-info":[{"award-number":["UMREG060-2024"]}],"id":[{"id":"10.13039\/501100004781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>New-onset refractory status epilepticus (NORSE) is a life-threatening neurological condition that emerges abruptly in individuals without a prior history of epilepsy and is characterised by seizures that are refractory to standard antiseizure medications. NORSE is associated with high mortality and long-term neurological deficits, and autoimmune encephalitis (AIE) represents a major identifiable cause of NORSE. Growing evidence implicates immune-mediated mechanisms as central drivers of NORSE; however, existing studies have focused predominantly on innate immune dysregulation, including cytokine-driven neuroinflammation and microglial activation, whilst the role of adaptive immune mechanisms in AIE-mediated NORSE remains relatively underexplored. This review synthesises current evidence linking adaptive immune responses in NORSE pathogenesis, with particular emphasis on B and T lymphocytes in shaping neuroinflammation. B cell\u2013mediated response is implicated in NORSE cases associated with AIE where autoantibodies such as anti-N-methyl-D-aspartate receptor (NMDAR) disrupt neuronal signalling and contribute to seizure generation. Beyond humoral immunity, T-cell subsets, for instance, cytotoxic T cells, contribute to neuronal damage through recognition of neuronal intracellular antigens. Emerging immunomodulatory therapies targeting adaptive immune components are also discussed, including monoclonal antibody therapies and innovative approaches inspired by conventional chimeric antigen receptor (CAR) T-cell technology. A deeper understanding of the complex interplay between innate and adaptive immune responses is essential to elucidate disease mechanisms and guide future development of more precise mechanism-based therapeutic strategies for NORSE.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1874730","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:50:57Z","timestamp":1785408657000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adaptive immune dysregulation drives new-onset refractory status epilepticus"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhi-Ying","family":"Phong","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Lei","family":"Fong","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kheng-Seang","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhailah","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Gee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Soong","family":"Khoo","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Yeng","family":"Looi","sequence":"additional","affiliation":[{"name":"School of Biosciences, Faculty of Health & Medical Sciences, Taylor\u2019s University","place":["Subang Jaya, Malaysia"]},{"name":"Department of Biotechnology, Faculty of Applied Sciences, UCSI Universitiy","place":["Cheras, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Fen","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804766-8.00025-X","article-title":"Epilepsy and aging","volume":"167","author":"Kotloski","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12944","article-title":"NORSE seasonality may vary geographically in adults","volume":"9","author":"Bolle","year":"2024","journal-title":"Epilepsia Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17523","article-title":"The etiology and mortality of new-onset refractory status epilepticus (NORSE) in adults: A systematic review and meta-analysis","volume":"64","author":"Tharmaraja","year":"2023","journal-title":"Epilepsia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001940","article-title":"New-onset refractory status epilepticus: Etiology, clinical features, and outcome","volume":"85","author":"Gaspard","year":"2015","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03250.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children","volume":"52","author":"Kramer","year":"2011","journal-title":"Epilepsia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1426051","article-title":"NORSE\/FIRES: how can we advance our understanding of this devastating condition","volume":"15","author":"Champsas","year":"2024","journal-title":"Front Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15149","article-title":"Unraveling the enigma of new-onset refractory status epilepticus: a systematic review of aetiologies","volume":"29","author":"Lattanzi","year":"2022","journal-title":"Eur J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010044","article-title":"Seizures, epilepsy, and NORSE secondary to autoimmune encephalitis: A practical guide for clinicians","volume":"11","author":"Vogrig","year":"2022","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/nu16010001","article-title":"Effects of malnutrition on the immune system and infection and the role of nutritional strategies regarding improvements in children's health status: A literature review","volume":"16","author":"Morales","year":"2023","journal-title":"Nutrients"},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.26627","article-title":"Cytokines in new-onset refractory status epilepticus predict outcomes","volume":"94","author":"Hanin","year":"2023","journal-title":"Ann Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/epi.70146","article-title":"Exploring pathways leading to drug-resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus","volume":"67","author":"Hanin","year":"2026","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neurol.2021.12.005","article-title":"New onset refractory status epilepticus: State of the art","volume":"178","author":"Perin","year":"2022","journal-title":"Rev Neurol (Paris)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2025.104406","article-title":"Immune dysregulation in new-onset refractory status epilepticus (NORSE): Current insights and therapeutic perspectives","volume":"47","author":"Hanin","year":"2025","journal-title":"Brain Dev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17576","article-title":"Blood-brain barrier damage and new onset refractory status epilepticus: An exploratory study using dynamic contrast-enhanced magnetic resonance imaging","volume":"64","author":"Li","year":"2023","journal-title":"Epilepsia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0217-x","article-title":"Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy","volume":"15","author":"Vezzani","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200259","article-title":"Single-cell transcriptomic analyses of brain parenchyma in patients with new-onset refractory status epilepticus (NORSE)","volume":"11","author":"Hanin","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11726-x","article-title":"Neuropathology of new-onset refractory status epilepticus (NORSE)","volume":"270","author":"Hanin","year":"2023","journal-title":"J Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2008.10.002","article-title":"Antagonism of peripheral inflammation reduces the severity of status epilepticus","volume":"33","author":"Marchi","year":"2009","journal-title":"Neurobiol Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.0105-2896.2010.00896.x","article-title":"Perforin: structure, function, and role in human immunopathology","volume":"235","author":"Voskoboinik","year":"2010","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmy137","article-title":"Th17 cells were recruited and accumulated in the cerebrospinal fluid and correlated with the poor prognosis of anti-NMDAR encephalitis","volume":"50","author":"Zeng","year":"2018","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16742","article-title":"Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy","volume":"62","author":"Ouedraogo","year":"2021","journal-title":"Epilepsia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws212","article-title":"Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system","volume":"135","author":"Larochelle","year":"2012","journal-title":"Brain"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.5.2107","article-title":"MUC18\/MCAM (CD146), an activation antigen of human T lymphocytes","volume":"158","author":"Pickl","year":"1997","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040443","article-title":"Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS","volume":"7","author":"Flanagan","year":"2012","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nri.2016.123","article-title":"Cytokine networks in neuroinflammation","volume":"17","author":"Becher","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12974-016-0507-9","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid","volume":"13","author":"Liba","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2011.648762","article-title":"Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders","volume":"122","author":"Ulusoy","year":"2012","journal-title":"Int J Neurosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171285","article-title":"Peripherally derived T regulatory and gammadelta T cells have opposing roles in the pathogenesis of intractable pediatric epilepsy","volume":"215","author":"Xu","year":"2018","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2014.03.004","article-title":"Participation of interleukin 17A in neuroimmune interactions","volume":"41","author":"Moynes","year":"2014","journal-title":"Brain Behav Immun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102335","article-title":"Negative effects of brain regulatory T cells depletion on epilepsy","volume":"217","author":"Yue","year":"2022","journal-title":"Prog Neurobiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bj.2020.05.007","article-title":"Diminished toll-like receptor response in febrile infection-related epilepsy syndrome (FIRES)","volume":"43","author":"Hsieh","year":"2020","journal-title":"BioMed J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-020-00375-7","article-title":"Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders","volume":"15","author":"Machhi","year":"2020","journal-title":"Mol Neurodegener"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.815347","article-title":"Microglia polarization from M1 to M2 in neurodegenerative diseases","volume":"14","author":"Guo","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000464388","article-title":"Treg cells protect dopaminergic neurons against MPP+ neurotoxicity via CD47-SIRPA interaction","volume":"41","author":"Huang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202154096","article-title":"Helminthic dehydrogenase drives PGE(2) and IL-10 production in monocytes to potentiate Treg induction","volume":"23","author":"Prodjinotho","year":"2022","journal-title":"EMBO Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578430","article-title":"IT-DEX and B cell depletion in a child with anti-GAD 65 autoimmune encephalitis presenting as NORSE: A case report","volume":"395","author":"Yarimi","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12036","article-title":"Cerebrospinal fluid CD19(+) B-cell expansion in N-methyl-D-aspartate receptor encephalitis","volume":"55","author":"Dale","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228c136","article-title":"Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis","volume":"77","author":"Martinez-Hernandez","year":"2011","journal-title":"Neurology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/pcn.13627","article-title":"Single-cell RNA sequencing reveals diverse B cell phenotypes in patients with anti-NMDAR encephalitis","volume":"78","author":"Li","year":"2024","journal-title":"Psychiatry Clin Neurosci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.09.017","article-title":"Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts","volume":"265","author":"Hachiya","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16275","article-title":"Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus","volume":"60","author":"Kothur","year":"2019","journal-title":"Epilepsia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-93","article-title":"CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation","volume":"9","author":"Kowarik","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.4.655","article-title":"B cell\u2013attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1\/CXCR5","volume":"187","author":"Legler","year":"1998","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: Real-world evidence from the GENERATE Registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24195","article-title":"Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis","volume":"76","author":"Moscato","year":"2014","journal-title":"Ann Neurol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.09.018","article-title":"New onset refractory status epilepticus (NORSE)","volume":"68","author":"Sculier","year":"2019","journal-title":"Seizure"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnp.2017.06.003","article-title":"Limbic and new onset refractory tonic status epilepticus (NORSE) in anti-NMDAR encephalitis","volume":"2","author":"Kaplan","year":"2017","journal-title":"Clin Neurophysiol Pract"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2021.70431","article-title":"Anti-N-methyl D-aspartate receptor encephalitis presenting with the new-onset refractory status epilepticus","volume":"10","author":"Alemdar","year":"2023","journal-title":"North Clin Istanb"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.18700\/jnc.190115","article-title":"Favorable clinical course after early-intensive immunotherapy for new-onset refractory status epilepticus","volume":"13","author":"Kim","year":"2020","journal-title":"J Neurocrit Care"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21589","article-title":"AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann Neurol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.neuron.2018.07.048","article-title":"Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction","volume":"100","author":"Haselmann","year":"2018","journal-title":"Neuron"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3988\/jcn.2016.12.1.1","article-title":"The diagnosis and treatment of autoimmune encephalitis","volume":"12","author":"Lancaster","year":"2016","journal-title":"J Clin Neurol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2025.1586005","article-title":"Clinical characteristics and outcome in patients with anti-AMPAR2 encephalitis: a case series and literature review","volume":"19","author":"Wang","year":"2025","journal-title":"Front Hum Neurosci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1528-1157.2001.042suppl.3008.x","article-title":"GABAergic mechanisms in epilepsy","volume":"42","author":"Treiman","year":"2001","journal-title":"Epilepsia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4944-04.2005","article-title":"Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus","volume":"25","author":"Naylor","year":"2005","journal-title":"J Neurosci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3426-07.2008","article-title":"Subunit-specific trafficking of GABA(A) receptors during status epilepticus","volume":"28","author":"Goodkin","year":"2008","journal-title":"J Neurosci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.018","article-title":"From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time","volume":"15","author":"van Sonderen","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B69","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12035-022-03011-1","article-title":"Multi-proteomic analysis revealed distinct protein profiles in cerebrospinal fluid of patients between anti-NMDAR encephalitis NORSE and cryptogenic NORSE","volume":"60","author":"Wang","year":"2023","journal-title":"Mol Neurobiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200403","article-title":"Identification of distinct biological groups of patients with cryptogenic NORSE via inflammatory profiling","volume":"12","author":"Guillemaud","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207068","article-title":"Bridging the gap: Tailoring an approach to treatment in febrile infection-related epilepsy syndrome","volume":"100","author":"Goh","year":"2023"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib treatment for refractory autoimmune encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8277-y","article-title":"Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study","volume":"263","author":"Heine","year":"2016","journal-title":"J Neurol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for\u00a0autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann Neurol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51755","article-title":"Drug-resistant seizures associated with hyperinflammatory monocytes in FIRES","volume":"10","author":"Howe","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.104","article-title":"Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice","volume":"132","author":"Elson","year":"2007","journal-title":"Gastroenterology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2022.9447","article-title":"Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema","volume":"14","author":"Bernardini","year":"2022","journal-title":"Dermatol Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7070078","article-title":"Multiple sclerosis: immunopathology and treatment update","volume":"7","author":"Dargahi","year":"2017","journal-title":"Brain Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028432","article-title":"Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation","volume":"6","author":"Zhang","year":"2011","journal-title":"PloS One"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2011.03.007","article-title":"IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells","volume":"25","author":"Sweeney","year":"2011","journal-title":"Brain Behav Immun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124802","article-title":"Interferon-beta suppresses murine Th1 cell function in the absence of antigen-presenting cells","volume":"10","author":"Boivin","year":"2015","journal-title":"PloS One"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514557986","article-title":"Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE","volume":"21","author":"Kieseier","year":"2015","journal-title":"Mult Scler"},{"key":"B89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005910","article-title":"EEG findings in CAR T-cell therapy-related encephalopathy","volume":"91","author":"Herlopian","year":"2018","journal-title":"Neurology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1177\/19418744211000980","article-title":"Recurrent status epilepticus in the setting of chimeric antigen receptor (CAR)-T cell therapy","volume":"12","author":"Reveron-Thornton","year":"2022","journal-title":"Neurohospitalist"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2024.7","article-title":"Frontal lobe status epilepticus related to CAR T-cell therapy responsive to anakinra","volume":"52","author":"Pensato","year":"2025","journal-title":"Can J Neurol Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1007\/s10072-024-07510-y","article-title":"Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy","volume":"45","author":"Pensato","year":"2024","journal-title":"Neurol Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.17.1375.34432","article-title":"Levetiracetam: a novel antiepileptic drug","volume":"21","author":"Hovinga","year":"2001","journal-title":"Pharmacotherapy"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.04.011","article-title":"Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans","volume":"23","author":"Guenther","year":"2014","journal-title":"Seizure"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: How to improve their persistence","volume":"13","author":"Lopez-Cantillo","year":"2022","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17988","article-title":"Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection-related epilepsy syndrome) versus without prior fever: An interim analysis","volume":"65","author":"Jimenez","year":"2024"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.70011","article-title":"Phenotype, outcome, interleukins, and miRNA levels assessment of new-onset refractory status epilepticus: A prospective cohort study","volume":"27","author":"Adiga","year":"2025","journal-title":"Epileptic Disord"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.00140.x","article-title":"Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus","volume":"12","author":"De Simoni","year":"2000","journal-title":"Eur J Neurosci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1874730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:50:59Z","timestamp":1785408659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1874730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":103,"alternative-id":["10.3389\/fimmu.2026.1874730"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1874730","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1874730"}}